Short answer
Adaptive Biotechnologies Corp (ADPT) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $71M (up 35.1% year over year) with net income of −$20M.
Q1 2026 key financials · XBRL
- Revenue
- $71M
- +35.1% YoY
- Net income
- −$20M
- +32.9% YoY
- Operating margin
- -27.1%
- EPS (diluted)
- −$0.13
- +35.0% YoY
Source: XBRL data from the Adaptive Biotechnologies Corp (ADPT) Q1 2026 10-Q on SEC EDGAR. USD.
Adaptive Biotechnologies Corp Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk-factors section provided; supplied text contains only Items 2–6 and signatures
- New insider-trading disclosure: Harlan Robins adopted a plan covering up to 984,800 shares through December 31, 2026
- Insider-trading compliance change: Kyle Piskel terminated his plan covering up to 173,901 shares and vested-share proceeds
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Adaptive Biotechnologies Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.